FIGURES AND TABLES
FROM:
Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma
J J Ord, E Streeter, A Jones, K Le Monnier, D Cranston, J Crew, S P Joel, M A Rogers, R E Banks, I S D Roberts and A L Harris
BACK TO ARTICLE
Figure 1.
Mean postdose urinary Suramin concentrations by dose level (see Table 1). This represents the concentration of urine drained from the bladder at the end of the 2-h instillation. Error bar equals 1 s.d. Differences between groups are highly significant (two-tailed t-test, variances not assumed to be equal P<0.01).
Full figure and legend (9K)
Figure 2.
Suramin interference with VEGF ELISA. Standard concentrations of VEGF were spiked with different levels of Suramin, and then the VEGF was measured.
Full figure and legend (29K)
Figure 3.
(A) Urine VEGF pre- and postdose by individual patient. Individual patients are indicated by a number from 1 to12. (B) Urine VEGF pre- and postdose grouped by dose level of Suramin. Three patients per level; difference between level 1 and other levels P
0.05 is seen at postdoses 1, 2, 3 and 5. Error bars equal s.e.m.
Figure 4.
SELDI profiles of urine samples from patient 9 on a SAX2 chip (A) and patient 12 on an H4 chip (B). Pre- and postdose 1 and 6, and 4 weeks postcessation of Suramin treatment. Arrows identify peaks that are either lost or gained.
Full figure and legend (70K)
Figure 5.
Staining for blood vessels in inflamed and noninflamed bladder with antibodies to CD31.
Full figure and legend (99K)
